TobaccoReporter logo

Tag: Zyn

  • Zyn Launches 1.5 Mg Option in UK

    Zyn Launches 1.5 Mg Option in UK

    Zyn launched Zyn X-Low, its lowest-strength nicotine pouch at 1.5mg, positioning it as an entry-level option for adult users new to the category, according to Talking Retail. The product expands Zyn’s UK and Ireland portfolio and is available in spearmint, black cherry, and cool mint via grocery, convenience, and wholesale channels, including Philip Morris’ Open retailer platform.

    “Expanding the range in this way allows us to meet a broader spectrum of adult nicotine preferences, strengthen the role of modern oral products in the marketplace, and further our ambition of achieving a smoke-free future,” said Dor Matot, head of Zyn UK and Ireland.

    The launch is backed by a nationwide marketing campaign aimed at highlighting strength choice and attracting first-time pouch users.

  • PMI Expands Partnership with Scuderia Ferrari HP

    PMI Expands Partnership with Scuderia Ferrari HP

    Philip Morris International announced an expanded partnership with Scuderia Ferrari HP and the Ferrari Challenge Trofeo Pirelli for the 2026 season and beyond. As part of the deal, PMI’s ZYN nicotine pouches will appear on select Scuderia Ferrari HP Formula 1 liveries, debuting at the Abu Dhabi Grand Prix on December 7.

    Stefano Volpetti, PMI’s President of Smoke-Free Products, said the collaboration reflects a shared drive to innovate and engage adult consumers. “By further enhancing our partnership with Scuderia Ferrari HP, we hope to accelerate the replacement of cigarettes, and we want our adult consumers of nicotine products, like ZYN, to embrace and enjoy every moment of this thrilling ride,” he said.

    Ferrari’s Lorenzo Giorgetti highlighted the partnership’s longevity and shared values, saying, “Our renewed collaboration with PMI continues a relationship that has lasted for over fifty years, grounded in scientific progress and long-term thinking.”

  • CEO Breaks Down PMI’s Smoke-free Future for Investors

    CEO Breaks Down PMI’s Smoke-free Future for Investors

    Philip Morris International used its appearance at the Morgan Stanley Global Consumer & Retail Conference yesterday (December 2) to reinforce that its smoke-free transition is a structural, irreversible shift, not a cyclical phase. CEO Jacek Olczak framed the dynamic succinctly, noting that smokers who switch to alternatives “very rarely” return to combustible cigarettes and that “smoke-free is essentially a one-way street.”

    Immediately before the event, PMI issued a brief communication to stabilize expectations, reaffirming the company’s guidance from Q3.

    Olczak said that PMI’s three-platform system—IQOS, ZYN, and vapor—is the most effective way to replace combustibles across all usage occasions. “Our objective is to equip the smoker with all three platforms. This is the best way to keep them away from smoking,” he said.

    ZYN remains PMI’s central U.S. growth engine. Following a one-time $100 million activation after supply shortages, “brand equity parameters of ZYN shot up by double-digits,” with the product capturing more than half of category growth despite maintaining a premium price.

    Internationally, IQOS is in its 11th consecutive year of expansion. Japan is nearing a 50/50 split between combustibles and smoke-free products, and prior category pauses were, Olczak said, “just a blip on the graph.” Upcoming Japanese tax equalization and European flavor bans are viewed as temporary disruptions rather than structural threats.

    PMI is also restructuring around a U.S./International dual-engine model, retiring its traditional regional setup. “We don’t really run the business by regions anymore,” Olczak said, positioning the company for future IQOS ILUMA authorization in the United States.

    Capital demands remain modest, with Olczak stressing that “adding extra capacity is only a few hundred million dollars — not a disturbing factor.” Overall, his message to investors was clear: the smoke-free shift is a one-way trajectory, and PMI believes it now has the platforms, structure, and regulatory environment to accelerate it.

  • FDA Schedules TPSAC Review of ZYN Applications

    FDA Schedules TPSAC Review of ZYN Applications

    The U.S. Food and Drug Administration announced a January 22, 2026, virtual meeting of the Tobacco Products Scientific Advisory Committee (TPSAC) to review modified risk tobacco product (MRTP) applications submitted by Swedish Match USA for 20 ZYN nicotine pouch products. These products—already authorized for sale through the PMTA pathway in January 2025—include flavors such as Cool Mint, Citrus, Coffee, Peppermint, and Wintergreen, each in 3 mg and 6 mg strengths. The company is seeking permission to market the pouches with the claim: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

    Under federal law, MRTP applications must demonstrate that a product, as actually used by consumers, reduces individual health risks and benefits overall population health. TPSAC’s review will focus on scientific evidence regarding ZYN’s relative health risks, consumer comprehension of the proposed claim, and the potential public health impact of granting a modified risk order. The meeting will be held virtually, open to the public, captioned, and recorded.

    Public comments may be submitted to Docket No. FDA-2025-N-0835 through January 21, 2026, with comments received by January 7 provided directly to TPSAC. The FDA is also inviting individuals to request oral presentation slots during the meeting’s public comment period. Redacted MRTP application materials are available on the FDA’s website, and the agency will consider all public input and TPSAC recommendations before issuing a final decision.

  • Haypp Reports Q3 2025 Results Amid U.S. Expansion Investments

    Haypp Reports Q3 2025 Results Amid U.S. Expansion Investments

    Haypp reported Q3 2025 net sales of SEK 952.1 million ($95.2 million), an 0.8% increase, driven by strong performance in nicotine pouches, which accounted for 68% of total oral nicotine volume with like-for-like (LFL) volume growth of 21% (LFL excludes the impact of the ZYN shortage, U.S. state closures, and tobacco sales discontinuations.) Gross margin rose to 18.8%, while adjusted EBITDA reached SEK 53.0 million ($5.3 million) and adjusted EBIT was SEK 33.4 million ($3.3 million). Operating profit fell to SEK 6.2 million ($620,000) and net profit to SEK 4.5 million, reflecting a SEK 17.2 million ($1.7 million) litigation settlement.

    Key developments included the return of ZYN to the U.S. market, early indicators of strong sales, and continued growth in Swedish and German vaping and heated tobacco products, which now make up over 70% of Haypp’s Emerging segment. UK nicotine vaping and HnB sales will be discontinued in Q4 2025 pending regulatory clarity.

    “[The] U.S. return of Zyn, U.S. market developments and gross margin expansion strengthen our foundation for growth,” said Gavin O’Dowd, Haypp president and CEO. “The benefits of Zyn’s return will be realized in Q4 2025 with promising early indicators.”

    Haypp also completed most of its global e-commerce platform migration, improving infrastructure for agile growth. CEO Gavin O’Dowd emphasized that U.S. market developments, innovative product availability, and gross margin expansion are strengthening the company’s foundation for future growth.

  • PMI Reports Strong Q3 Based on Smoke-Free Surge

    PMI Reports Strong Q3 Based on Smoke-Free Surge

    Today (October 21), Philip Morris International reported strong third-quarter 2025 results, with adjusted diluted earnings per share rising 17.3% to $2.24, while reported EPS increased 13.2% to $2.23. The company said it achieved record smoke-free gross profit, supported by higher volumes and favorable pricing. Net revenues grew 5.9% on an organic basis, and adjusted operating income rose 7.5%, driven by strong performance in smoke-free products, despite a 3.2% decline in cigarette volumes.

    PMI’s smoke-free portfolio continued to expand rapidly, now accounting for 41% of total net revenues and 42% of gross profit. Volumes of smoke-free products rose 16.6%, led by the IQOS heated tobacco line and ZYN nicotine pouches. IQOS strengthened its market share across Europe and Asia, while ZYN’s U.S. offtake surged 39% following its return to full availability. The e-vapor brand VEEV also posted a 91% jump in shipments, solidifying PMI’s diversified presence across smoke-free categories.

    Reflecting this momentum, PMI raised its full-year adjusted EPS guidance and boosted its quarterly dividend by 8.9% to $1.47 per share. CEO Jacek Olczak said the company’s smoke-free business “continues to outgrow the industry by a clear margin,” adding that PMI is “on track to exceed” its 2024–2026 growth targets. Despite regulatory challenges in some markets, the company remains focused on transitioning adult smokers toward smoke-free alternatives and expanding its portfolio in 100 markets worldwide.

  • PMI Launches VEEV in South Africa, Expands Smoke-Free Portfolio

    PMI Launches VEEV in South Africa, Expands Smoke-Free Portfolio

    Philip Morris South Africa (PMSA) launched its VEEV e-cigarette this week, completing the company’s trio of smoke-free products in the country alongside IQOS heated tobacco and ZYN nicotine pouches, according to BizCommunity. This makes South Africa one of just 20 countries globally offering all three categories, underscoring PMSA’s commitment to providing adult smokers with scientifically backed alternatives to combustible cigarettes.

    Jonathan Kwak, Director of Smoke-Free Products at PMSA, said the launch gives “adult smokers more options than before when considering scientifically substantiated alternatives to smoking” and is a critical step toward eliminating cigarette use. PMI says it has invested over $14 billion globally since 2008 in research and development of smoke-free products, which are now available in 97 markets and used by more than 41 million adult consumers worldwide.

    While emphasizing that quitting all tobacco and nicotine remains the best choice, Kwak said that switching entirely to smoke-free products can significantly reduce exposure to harmful chemicals produced by burning tobacco. “With our expanding offering, we aim to accelerate South Africa’s transition to a smoke-free future, aligning with harm-reduction principles already embraced in other public-health fields,” he said.

  • Haypp Group Returns ZYN to U.S. Online Portfolio

    Haypp Group Returns ZYN to U.S. Online Portfolio

    Haypp Group announced that ZYN nicotine pouches are once again available for online purchase through its U.S. platforms, Nicokick.com and Northerner.com. According to the company’s press release, the relaunch covers 10 products that received FDA Marketing Granted Orders, offered in 3 mg and 6 mg strengths across flavors such as cinnamon, spearmint, wintergreen, and citrus.

    Peter Grafström, President of Haypp Group U.S., said the move is centered on compliance and adult-only access. “As a responsible online retailer, our priority is ensuring Nicokick and Northerner provide 21 and over consumers with responsible access to tobacco leaf-free alternatives to traditional tobacco products,” he said. The company emphasized its Legal Age Access Only Program and regulatory alignment as key safeguards.

    Haypp said ZYN has been one its top sellers, accounting for 46% of total U.S. sales on Nicokick and Northerner in Q2 2024. With more than 200 smoke-free nicotine alternatives now available across its U.S. e-commerce sites, Haypp says the relaunch reflects both strong consumer demand and the growing role of online retail in the nicotine pouch category.

    For more information, visit Nicokick and Northerner. 

  • FDA Launches Pilot to Fast-Track Nicotine Pouch Reviews

    FDA Launches Pilot to Fast-Track Nicotine Pouch Reviews

    The U.S. Food and Drug Administration is set to fast-track reviews of nicotine pouches from Philip Morris International, Altria, Reynolds American, and Turning Point Brands in a pilot program launching Monday, according to Reuters. According to transcripts of an agency meeting last Friday, the agency aims to complete assessments by December, providing a quicker path to market for products like Zyn, on!, Velo, Fre, and Alp. The initiative comes amid pressure from the Trump administration to accelerate approvals and streamline the review process for the fastest-growing category of U.S. tobacco alternatives.

    The pilot program will reportedly feature reduced and expedited reviews, more frequent communication between FDA staff and companies, and a focus on essential scientific and safety data, including product characterization, manufacturing consistency, and abuse-liability information. For products already on the market without full authorization, the process could remove uncertainty over legality and potential enforcement actions. Tobacco firms have long lobbied for a faster FDA authorization route, noting that lengthy reviews have allowed competitors to capture market share in the meantime.

    “Adult nicotine and tobacco consumers are increasingly seeking nicotine pouches as a smoke-free alternative, and the industry is rapidly growing in response,” said Laura Leigh Oyler, vice president of U.S. Regulatory Affairs at Haypp Group, who will be speaking at GTNF 2025 in Brussels on the U.S. regulatory landscape. “These consumers deserve a marketplace of FDA-reviewed product choices to support their journey away from more harmful products. 

    “It makes sense that our government should also work to meet the demands of citizens, supporting a regulatory regime that quickly reviews well-designed and well-tested products from responsible and compliant manufacturers. This is a positive step not just for the regulator and the regulated industry, but for the millions of American adults looking for products they can trust.”

  • PMI Reaffirms 2025 EPS Outlook on IQOS, ZYN Momentum

    PMI Reaffirms 2025 EPS Outlook on IQOS, ZYN Momentum

    Philip Morris International reaffirmed its 2025 earnings forecast today (September 2) at the Barclays Global Consumer Staples Conference, projecting reported diluted EPS of $7.24–$7.37 and adjusted diluted EPS of $7.43–$7.56, representing 13–15% growth versus last year. PMI reported better-than-expected combustible volume recovery in Turkey and Egypt, alongside continued growth in IQOS, ZYN, and VEEV globally.

    “With strong volume momentum over the summer months, including IQOS and ZYN offtake, and despite increasing competition in smoke-free products, we are on track to deliver our full-year guidance of 13% to 15% adjusted diluted EPS growth in dollar terms, the strongest since 2011 excluding the pandemic recovery,” said Jacek Olczak, Chief Executive Officer.

    In the U.S., ZYN posted about 32% growth in the first eight weeks of Q3, prompting PMI to forecast shipment growth in line with offtake through year-end.

    An archived copy of the webcast is available at www.pmi.com/irapp.